Monthly information on share capital and company voting rights
12 avr. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
04 avr. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
14 mars 2023 17h00 HE
|
Cellectis Inc.
NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h45 HE
|
Cellectis Inc.
Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and...
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
06 mars 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
01 mars 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
GAIA BioMedicine and TreeFrog Therapeutics Announce Collaboration for the Expansion of Allogeneic NK-like Cells Against Solid Tumors
15 févr. 2023 10h00 HE
|
TreeFrog Therapeutics
FUKUOKA, Japan and BORDEAUX, France, Feb. 15, 2023 (GLOBE NEWSWIRE) -- GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and...
Monthly information on share capital and company voting rights
09 févr. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
07 févr. 2023 19h01 HE
|
Cellectis Inc.
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
03 févr. 2023 09h33 HE
|
Cellectis Inc.
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering...